

“Pre-clinical to Phase IV Urology Research & Development Partnership Developed”

Oakville, Canada; Toulouse, France. CMX Research Inc. and UROsphere SAS. are pleased to announce that they have developed an alliance to provide fully integrated preclinical-Phase IV contract research services to the biopharmaceutical and medical device industry. This pan-Atlantic partnership will take advantage of deep expertise in the development of Urology based compounds residing in both companies to efficiently move products from the bench to the bedside.

“We are very enthusiastic about building a comprehensive solution for the Urology drug and device development industry,” comments CMX Research Inc. CEO and practicing Urologist Dr. Richard Casey. “With over 18 years of clinical development experience and 360 trials implemented at CMX Research, coupled with the state-of-the-art *in vivo* and *in vitro* pre-clinical models offered through UROsphere, this partnership will be the first of its kind in the field of Urology”.

“UROsphere is excited about joining forces with CMX Research to provide the expertise and ability to develop treatments for urological pathologies from concept through registration and beyond,” explains Dr. Philippe Lluel, CEO of UROsphere. “UROsphere’s vast experience in investigating and validating early stage assets compliments the clinical expertise of CMX Research, providing clients with unique access to expertise across the full spectrum of drug development.

About CMX Research Inc.

CMX Research Inc. is an independent, full service CRO that provides highly experienced clinical project management teams to monitor Phase I-IV clinical research trials across Canada. We excel at fully integrating with our clients’ project teams to ensure that medical research is conducted ethically, effectively and efficiently.

Since 1995 we have completed over 360 Phase I-IV projects with our clients that include biotech, pharmaceutical and medical device companies.

CMX Research Inc. manages the largest urology network in Canada, representing over 100 physicians and 120 coordinators within the research community setting. Our highly experienced clinical investigators and research coordinators cover an array of therapeutic indications with an emphasis in urology.

Contact:

Roger Sharpe, M.B.A.

Director, Business Development

(416) 435-1746

rsharpe@cmxres.com

About Urosphere SAS.

UROsphere is an independent Contract Research company specializing in preclinical urogenital and renal assays. The company was founded in 2004 by Dr Philippe Lluel and Dr Stefano Palea, two senior researchers with decades of experience in large pharmaceutical companies testing and developing drug candidates for urological indications.

Through our optimized pharmacology platform, we conduct assays to investigate new therapies and combinations of existing therapies for lower urinary tract (LUTs) pathologies.

UROsphere's headquarters and laboratories are located in Toulouse, France. The company also has a representative in Philadelphia, Pennsylvania, USA.

Contact:

Philippe Lluel, CEO

UROsphere S.A.S.

Faculté des Sciences Pharmaceutiques

35, Chemin des Maraîchers

31062 Toulouse Cedex 09

France

Phone : + 33-5-61 55 58 04

FAX : + 33-5-62 25 98 16

E-mail : philippe.lluel@urosphere.com

Site Internet : www.urosphere.com